<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83953">
  <stage>Registered</stage>
  <submitdate>22/05/2009</submitdate>
  <approvaldate>11/06/2009</approvaldate>
  <actrnumber>ACTRN12609000435280</actrnumber>
  <trial_identification>
    <studytitle>Is a Patented Strain of Bacillus coagulans Probiotic a Viable Adjunct Therapy for Relieving Symptoms of Rheumatoid Arthritis?</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled Study of Bacillus coagulans as Adjunct Therapy for the Relief of Symptoms of Rheumatoid Arthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>rheumatoid arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A patented strain of Bacillus coagulans probiotic in caplet form taken orally with water once daily for 60 days. Each caplet/dose contains 2 x 10 9 colony-forming units (CFUs).</interventions>
    <comparator>Identical appearing placebo caplets (985 mg) containing microcrystalline cellulose were taken orally with water once daily for 60 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain assessment score and pain scale. American College of Rheumatology (ACR) questionnaire and Health Assessment Questionnaire (HAQ) were used to assess symptom severity compared with baseline self-assessment scores. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were used to assess change in inflammation.</outcome>
      <timepoint>60 days following the commencement of treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Functional ability and safety. The Health Assessment Questionnaire (HAQ) was used to assess the ability to arise, walk 2 miles, perform daily activities, dress and groom, eat, reach, grip, and maintain personal hygiene.</outcome>
      <timepoint>60 days following the commencement of treatment.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects were diagnosed with rheumatoid arthritis at least a year prior to the study</inclusivecriteria>
    <inclusiveminage>36</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>82</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, chronic inflammatory bowel disease, kidney or liver disease, and subjects taking &gt;10 mg/day of prednislone or other probiotic products</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>23/06/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>45</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>David R. Mandel, MD</primarysponsorname>
    <primarysponsoraddress>David R. Mandel, MD, Inc.
6551 Wilson Mills Rd, #106
Mayfield Village, OH  44143</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ganeden Biotech, Inc.</fundingname>
      <fundingaddress>5915 Landerbrook Dr., Suite 304
Mayfield Heights, OH 44124</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Certain probiotics have demonstrated the ability to lessen the symptoms of arthritis in animals and humans. This clinical trial was conducted to evaluate the effects of the probiotic Bacillus coagulan GBI-30, 6086 on symptoms and functional capacity in patients with rheumatoid arthritis when taken in combination with pharmacological anti-arthritic medications.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David R. Mandel, MD</name>
      <address>David R. Mandel, MD, Inc.
6551 Wilson Mills Rd, #106
Mayfield Village, OH  44143</address>
      <phone>1-440-449-8277</phone>
      <fax />
      <email>katy@mandelmd.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>David R. Mandel, MD</name>
      <address>David R. Mandel, MD, Inc.
6551 Wilson Mills Rd, #106
Mayfield Village, OH  44143</address>
      <phone>1-440-449-8277</phone>
      <fax />
      <email>katy@mandelmd.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>